"Azithromycin for sarcoidosis cough: an open-label exploratory clinical trial". Simon D. Fraser, Susannah Thackray-Nocera, Marica Shepherd, Rachel Flockton, Caroline Wright, Wayne Sheedy, Kayleigh Brindle, Alyn H. Morice, Paul M. Kaye, Michael G. Crooks and Simon P. Hart. *ERJ Open Res* 2020; 6: 00534-2020.

This article was originally published in 2020. During recent analysis of exploratory endpoints, the authors realised that one patient who was recorded as taking oral steroid therapy had not actually taken any prednisolone for over a year prior to their participation in the trial. In addition, a small number of minor data transcription errors had occurred during the original analyses that formed this article. The authors apologise for these errors.

The authors have re-run the statistical analyses using the corrected data. The primary endpoint (cough counting) is unaffected. Three patient-reported secondary endpoints in table 2 have undergone minor alterations. Statistical significance is not affected for any comparisons. Interpretation and conclusions are unaffected.

Tables 1 and 2 have been corrected in the article itself, and the corrected versions are shown below. Corrected values are presented in italics in the versions below only.

Consequently, the sentence in the abstract that previously read "Five were taking oral corticosteroids and none were taking other immunosuppressants" has been changed to "Four were taking oral corticosteroids and none were taking other immunosuppressants".

TABLE 1 Demographic and clinical details of 21 recruited patients with sarcoidosis

Age years	57 (48–71)
Male/female	9/12
Years since diagnosis	3 (1–13)
Scadding chest radiography stage 1/2/3	2/6/12
FEV_1 % predicted	87.5 (52–131)
FVC % predicted	91.5 (63–128)
FEV_1/FVC ratio	0.75 (0.55–0.93)
QTc interval ms	427 (370–463)
Oral corticosteroid therapy	*4*
Other immunomodulatory therapy	0
Inhaled corticosteroids	3
Number of coughs in 24 h	228 (43–1950)
Number of coughs·h^{-1}	10 (2–81)
Cough severity VAS mm	31 (9–94)
Urge to cough VAS mm	26 (8–94)
Leicester cough questionnaire score	15.96 (5.07–19.74)
King's sarcoidosis questionnaire GH score	50.7 (23.8–100)

Data are presented as median (range) or n. FEV_1: forced expiratory volume in 1 s; FVC: forced vital capacity; VAS: visual analogue scale.

TABLE 2 Secondary end-points

	Baseline	1 month	3 months	Change from baseline to 3 months	p-value (Friedman's test)
Cough severity VAS	Median *31.0* (9, 94)	*23.0* (3, 88)	19.0 (0, 62)	*−11.0* (−93, 20)	*0.003*
	Mean *39.8 (26.8)*	*33.6* (25.2)	19.8 (17.7)	*−19.3 (27.0)*	
Cough urge VAS	Median 26.0 (8, 94)	26.0 (2, 83)	19.0 (0, 61)	*−7.0* (−83, 42)	*0.163*
	Mean *37.7 (24.9)*	*32.8 (23.1)*	22.2 *(18.4)*	*−14.5 (28.3)*	
LCQ	Median 15.96 (5.07, 19.74)	17.6 (6.11, 20.75)	19.02 (14.93, 20.38)	1.85 (−1.17, 12.18)	0.006
	Mean 14.63 (4.07)	16.68 (3.41)	18.23 (1.76)	3.47 (4.0)	
KSQ_GH	Median 50.7 (23.8, 100)	61.9 (29.4, 100)	72.25 (39.9, 100)	16.3 (−13.8, 47.1)	0.001
	Mean *53.2* (18.3)	63.0 (18.1)	69.63 (15.4)	*17.2 (15.7)*	
KSQ_lung	Median 50.2 (29.0, 68.0)	52.6 (33.6, 77.1)	61.95 (41.6, 100)	6.5 (−1.3, 34.8)	0.001
	Mean 52.0 (10.4)	54.5 (12.0)	62.5 (14.0)	10.7 (11.3)	
KSQ_lung_GH	Median 58.1 (36.7, 74.7)	58.7 (41.9, 86.1)	66.25 (50.1, 91.5)	10.7 (−2.3, 26.8)	0.001
	Mean 57.3 (9.1)	61.9 (11.6)	67.58 (10.4)	10.6 (8.3)	

Data are presented as median (range) and mean (SD). VAS: visual analogue scale; LCQ: Leicester cough questionnaire; KSQ: King's sarcoidosis questionnaire (presented as general health (GH), lung and combined lung-GH domains).